NanoMosaic, a leader in advanced analytical technologies for cell and gene therapy development and manufacturing, today announced that the FDA's Center for Biologics Evaluation and Research (CBER) has ...

With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Sensorion has announced a $71.9m reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...

The global cell and gene therapy market is experiencing explosive growth. Key growth factors include rising chronic/genetic disease prevalence, advancements in gene editing (CRISPR) and viral vectors, ...

GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting ...